The Influence of Metabolism on Drug Response in Cancer

Zaal, Esther A.; Berkers, Celia R.

doi:10.3389/fonc.2018.00500

Cited by 272Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

The Influence of Metabolism on Drug Response in Cancer

Open access

Zaal, Esther A., Berkers, Celia R.·2018·Frontiers in Oncology

DOI 10.3389/fonc.2018.00500PMC PMC6230982

Open this paper in CoChat — free account Open PDF

Abstract

Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in the treatment of cancers and occurs in virtually every type of anti-cancer therapy. Therefore, understanding how resistance can be prevented, targeted and predicted becomes increasingly important to improve cancer therapy. In the last decade, it has become apparent that alterations in cellular metabolism are a hallmark of cancer cells and that a rewired metabolism is essential for rapid tumor growth and proliferation. Recently, metabolic alterations have been shown to play a role in the sensitivity of cancer cells to widely-used first-line chemotherapeutics. This suggests that metabolic pathways are important mediators of resistance toward anticancer agents. In this review, we highlight the metabolic alterations associated with resistance toward different anticancer agents and discuss how metabolism may be exploited to overcome drug resistance to classical chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fonc.2018.00500

Cites

186 of 186 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Alterations in cellular metabolism are essential for rapid tumour proliferation and affect the sensitivity of cancer cells to various drugs.
“Alterations in cellular metabolism are essential for rapid tumour proliferation and affect the sensitivity of cancer cells to various drugs [133].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [133]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · see citing works
On the origin of cancer cells
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · see citing works
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 11× · see citing works
“AN, 6-aminonicotinamide; ATP, adenosine triphosphate; BSO, buthionine sulfoximine; CPT1, carnitine palmitoyl transferase 1; DCA, dichloroacetate; ETC, electron transport chain; FASN, fatty acid synthase; FH, fumarate hydratase; G6PD, glucose-6-phosphate dehydrogenase; GCLC, glutathione cysteine ligase; GLS, glutaminas…”
BackgroundInfluential
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · see citing works
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · see citing works
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works
AMPK: guardian of metabolism and mitochondrial homeostasis
Herzig, S., & Shaw, R. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.95 · Cited by 4,094 · see citing works
HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · see citing works
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · see citing works
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · see citing works
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622 · see citing works
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463 · see citing works
Renal and Extrarenal Effects of Gum Arabic (Acacia Senegal) - What Can be Learned from Animal Experiments?
Nasir, O. (2013) · Kidney & Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331 · see citing works
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,177 · see citing works
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124 · see citing works
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 1× · see citing works
“Loss-of-function mutations in these genes are associated with tumorigenesis [reviewed in (82)] and result in the accumulation of succinate and fumarate, respectively, both of which function as oncometabolites (83, 84).”
Background
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001 · see citing works
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946 · see citing works
Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806 · see citing works
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770 · see citing works
Glucose feeds the TCA cycle via circulating lactate
Hui, S., Ghergurovich, J. M., Morscher, R. J., Jang, C., Teng, X., Lu, W., Esparza, L. A., Reya, T., Zhan, L., Yanxiang Guo, J., et al. (2017) · Nature · doi:10.1038/nature24057 · Cited by 1,721 · see citing works
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,686 · see citing works
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683 · see citing works
The multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651 · see citing works
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635 · see citing works
Nutrition Needs of Mammalian Cells in Tissue Culture
Eagle, H. (1955) · Science · doi:10.1126/science.122.3168.501 · Cited by 1,619 · see citing works
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505 · see citing works
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · see citing works
The pentose phosphate pathway and cancer
Patra, K. C., & Hay, N. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.06.005 · Cited by 1,444 · see citing works
Targeting cancer metabolism: a therapeutic window opens
Heiden, M. G. V. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,409 · see citing works
An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis
Birsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388 · see citing works
HIF-1: upstream and downstream of cancer metabolism
Semenza, G. L. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.10.009 · Cited by 1,381 · see citing works
MYC, Metabolism, and Cancer
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375 · see citing works
Cancer metabolism: fatty acid oxidation in the limelight
Carracedo, A., Cantley, L. C., & Pandolfi, P. P. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3483 · Cited by 1,316 · see citing works
Mitochondria and neuronal survival
Nicholls, D. G., & Budd, S. L. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.1.315 · Cited by 1,243 · see citing works
Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.
Reitzer, L. J., Wice, B. M., & Kennell, D. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30124-2 · Cited by 1,240 · see citing works
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229 · see citing works
Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells
Sullivan, L. B., Gui, D. Y., Hosios, A. M., Bush, L. N., Freinkman, E., & Vander Heiden, M. G. (2015) · Cell · doi:10.1016/j.cell.2015.07.017 · Cited by 1,173 · see citing works
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,147 · see citing works
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., Heffron, G., Metallo, C. M., Muranen, T., Sharfi, H., et al. (2011) · Nature Genetics · doi:10.1038/ng.890 · Cited by 1,120 · see citing works
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2817 · Cited by 1,057 · see citing works
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007 · see citing works
Self-citation
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A. M., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 995 · see citing works
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931 · see citing works
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913 · see citing works
Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism
Farge, T., Saland, E., de Toni, F., Aroua, N., Hosseini, M., Perry, R., Bosc, C., Sugita, M., Stuani, L., Fraisse, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0441 · Cited by 912 · see citing works
Metabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853 · see citing works
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816 · see citing works
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme
Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C., & Guha, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101470 · Cited by 789 · see citing works
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081162 · Cited by 777 · see citing works
Acetate is a bioenergetic substrate for human glioblastoma and brain metastases
Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K. J., Singh, D. K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S. G., Kovacs, Z., Foong, C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.025 · Cited by 760 · see citing works
Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness
Conklin, K. A. (2004) · Integrative Cancer Therapies · doi:10.1177/1534735404270335 · Cited by 752 · see citing works
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 705 · see citing works
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Mazurek, S. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.005 · Cited by 694 · see citing works
Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672 · see citing works
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661 · see citing works
Serine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661 · see citing works
Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells
Hosios, A. M., Hecht, V. C., Danai, L. V., Johnson, M. O., Rathmell, J. C., Steinhauser, M. L., Manalis, S. R., & Vander Heiden, M. G. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.02.012 · Cited by 641 · see citing works
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
Kaplon, J., Zheng, L., Meissl, K., Chaneton, B., Selivanov, V. A., Mackay, G., van der Burg, S. H., Verdegaal, E. M. E., Cascante, M., Shlomi, T., et al. (2013) · Nature · doi:10.1038/nature12154 · Cited by 633 · see citing works
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras -driven cancers
Mayers, J. R., Torrence, M. E., Danai, L. V., Papagiannakopoulos, T., Davidson, S. M., Bauer, M. R., Lau, A. N., Ji, B. W., Dixit, P. D., Hosios, A. M., et al. (2016) · Science · doi:10.1126/science.aaf5171 · Cited by 582 · see citing works
Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells
Labuschagne, C. F., van den Broek, N. J. F., Mackay, G. M., Vousden, K. H., & Maddocks, O. D. K. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.045 · Cited by 576 · see citing works
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 574 · see citing works
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 568 · see citing works
The emerging role and targetability of the TCA cycle in cancer metabolism
Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H. (2017) · Protein & Cell · doi:10.1007/s13238-017-0451-1 · Cited by 558 · see citing works
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Shukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King, R. J., Abrego, J., Goode, G. D., Dasgupta, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.004 · Cited by 536 · see citing works
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K. M., Tardito, S., Holyoake, T. L., Helgason, G. V., & Gottlieb, E. (2017) · Nature Medicine · doi:10.1038/nm.4399 · Cited by 533 · see citing works
Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stressPreprint
Zaugg, K., Yao, Y., Reilly, P. T., Kannan, K., Kiarash, R., Mason, J. M., Huang, P., Sawyer, S. K., Fuerth, B. J., Faubert, B., et al. (2011) · Genes & Development · doi:10.1101/gad.1987211 · Cited by 493 · see citing works
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G. G., Cavo, M., Orlowski, R. Z., Miguel, J. F. S., Palumbo, A. P., & Harousseau, J. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 491 · see citing works
Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
Hu, Y., DeLay, M., Jahangiri, A., Molinaro, A. M., Rose, S. D., Carbonell, W. S., & Aghi, M. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3831 · Cited by 484 · see citing works
Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis
Green, C. R., Wallace, M., Divakaruni, A. S., Phillips, S. A., Murphy, A. N., Ciaraldi, T. P., & Metallo, C. M. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1961 · Cited by 471 · see citing works
Over-expression of facilitative glucose transporter genes in human cancer
Yamamoto, T., Seino, Y., Fukumoto, H., Koh, G., Yano, H., Inagaki, N., Yamada, Y., Inoue, K., Manabe, T., & Imura, H. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91263-r · Cited by 465 · see citing works
Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J. J., van Zantwijk, C. H., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 459 · see citing works
Self-citation
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 443 · see citing works
Self-citation
Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells
Maddocks, O. D. K., Labuschagne, C. F., Adams, P. D., & Vousden, K. H. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.014 · Cited by 440 · see citing works
Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
Hitosugi, T., Zhou, L., Elf, S., Fan, J., Kang, H., Seo, J. H., Shan, C., Dai, Q., Zhang, L., Xie, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.020 · Cited by 434 · see citing works
Akt-dependent transformation: there is more to growth than just surviving
Plas, D. R., & Thompson, C. B. (2005) · Oncogene · doi:10.1038/sj.onc.1209097 · Cited by 427 · see citing works
Oncometabolites: linking altered metabolism with cancer
Yang, M. H., Soga, T., & Pollard, P. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67228 · Cited by 424 · see citing works
Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation
Ye, J., Mancuso, A., Tong, X., Ward, P. S., Fan, J., Rabinowitz, J. D., & Thompson, C. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204176109 · Cited by 410 · see citing works
Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer
Yalçın, A., Telang, S., Clem, B. F., & Chesney, J. A. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.003 · Cited by 407 · see citing works
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy
Sullivan, L. B., Gui, D. Y., & Heiden, M. G. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.85 · Cited by 406 · see citing works
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, Ø., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395 · see citing works
Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress
Krishnan, N., Dickman, M. B., & Becker, D. F. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.10.054 · Cited by 391 · see citing works
Acute Activation of Oxidative Pentose Phosphate Pathway as First-Line Response to Oxidative Stress in Human Skin Cells
Kuehne, A., Emmert, H., Soehle, J., Winnefeld, M., Fischer, F. F., Wenck, H., Gallinat, S., Terstegen, L., Lucius, R., Hildebrand, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.017 · Cited by 380 · see citing works
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J. J., Stewart, A. K., Reece, D. E., Chung, K. C., & Tiedemann, R. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.009 · Cited by 380 · see citing works
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374 · see citing works
Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release
Goetze, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1055 · Cited by 356 · see citing works
Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy
Swamy, M., Pathak, S., Grzes, K. M., Damerow, S., Sinclair, L. V., van Aalten, D. M. F., & Cantrell, D. A. (2016) · Nature Immunology · doi:10.1038/ni.3439 · Cited by 353 · see citing works
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
Atsumi, T., Chesney, J. A., Metz, C. N., Leng, L., Donnelly, S. C., Makita, Z., Mitchell, R., & Bucala, R. (2002) · PubMed · Cited by 322 · see citing works
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309 · see citing works
Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
Zhao, Y., Liu, H., Liu, Z., Ding, Y., LeDoux, S. P., Wilson, G. L., Voellmy, R. W., Lin, Y., Lin, W., Nahta, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0127 · Cited by 290 · see citing works
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 284 · see citing works
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Zhang, G., Frederick, D. T., Wu, L. W., Wei, Z., Krepler, C., Srinivasan, S., Chae, Y. C., Xu, X., Choi, H., Dimwamwa, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82661 · Cited by 282 · see citing works
Tumour-specific proline vulnerability uncovered by differential ribosome codon reading
Loayza‐Puch, F., Rooijers, K., Buil, L. C. M., Zijlstra, J., Vrielink, J. A. F. O., Lopes, R., Ugalde, A. P., Breugel, P. C. V., Hofland, I., Wesseling, J., et al. (2016) · Nature · doi:10.1038/nature16982 · Cited by 272 · see citing works
Mitochondria in cancer: Not just innocent bystanders
Frezza, C., & Gottlieb, E. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.008 · Cited by 267 · see citing works
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells
Janzer, A., German, N. J., Gonzalez-Herrera, K. N., Asara, J. M., Haigis, M. C., & Struhl, K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409844111 · Cited by 264 · see citing works
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249 · see citing works
PET/CT imaging in cancer: current applications and future directions
Farwell, M. D., Pryma, D. A., & Mankoff, D. A. (2014) · Cancer · doi:10.1002/cncr.28860 · Cited by 230 · see citing works
De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer
Tadros, S., Shukla, S. K., King, R. J., Gunda, V., Vernucci, E., Abrego, J., Chaika, N. V., Yu, F., Lazenby, A. J., Berim, L. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3062 · Cited by 223 · see citing works
The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
Lo, M., Ling, V. W. T., Wang, Y. Z., & Gout, P. W. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604485 · Cited by 222 · see citing works
MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies
Baek, G., Tse, Y. F., Hu, Z., Cox, D., Buboltz, N., McCue, P. A., Yeo, C. J., White, M. A., DeBerardinis, R. J., Knudsen, E. S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.025 · Cited by 221 · see citing works
A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction
Liu, H., Liu, Y., & Zhang, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0445 · Cited by 217 · see citing works
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 211 · see citing works
Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer
Lien, E. C., Lyssiotis, C. A., & Cantley, L. C. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_3 · Cited by 211 · see citing works
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Maiso, P., Huynh, D., Moschetta, M., Sacco, A., Aljawai, Y. M., Mishima, Y., Asara, J. M., Roccaro, A. M., Kimmelman, A. C., & Ghobrial, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3400 · Cited by 208 · see citing works
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. J. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189 · see citing works
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., van den Broek, N. J. F., Hogan, K., Tang, H., Virós, A., Martin, M. J., Galbraith, L. C. A., Girotti, M. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 183 · see citing works
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Zaal, E. A., Wu, W., Jansen, G., Zweegman, S., Cloos, J. J., & Berkers, C. R. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0169-9 · Cited by 182 · see citing works
Self-citation
Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor
Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet‐Martino, M., Balayssac, S., Rocchi, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1420 · Cited by 179 · see citing works
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 177 · see citing works
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
Franke, N. E., Niewerth, D., Assaraf, Y. G., van Meerloo, J., Vojtekova, K., van Zantwijk, C. H., Zweegman, S., Chan, E. T., Kirk, C. J., Geerke, D. P., et al. (2011) · Leukemia · doi:10.1038/leu.2011.256 · Cited by 176 · see citing works
Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells
Smith, B., Schafer, X., Ambeskovic, A., Spencer, C. M., Land, H., & Munger, J. C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.045 · Cited by 168 · see citing works
Mechanisms of lapatinib resistance in HER2-driven breast cancer
D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., Placido, S. D., Rosa, R., & Bianco, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.001 · Cited by 162 · see citing works
Reactive Oxygen Species‐Mediated Mechanisms of Action of Targeted Cancer Therapy
Teppo, H.-R., Soini, Y., & Karihtala, P. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1485283 · Cited by 162 · see citing works
Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers
Kremer, J. C., Prudner, B. C., Lange, S. E. S., Bean, G. R., Schultze, M., Brashears, C. B., Radyk, M. D., Redlich, N. J., Tzeng, S., Kami, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.077 · Cited by 160 · see citing works
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan
Vukovic, V., & Tannock, I. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.201 · Cited by 148 · see citing works
Emerging Role of the Pentose Phosphate Pathway in Hepatocellular Carcinoma
Kowalik, M. A., Columbano, A., & Perra, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00087 · Cited by 145 · see citing works
Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
Sanchez, W. Y., McGee, S. L., Connor, T., Mottram, B. M., Wilkinson, A., Whitehead, J. P., Vučković, S., & Catley, L. P. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.120 · Cited by 144 · see citing works
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
Soriano, G. P., Bešše, L., Li, N., Kraus, M., Bešše, A., Meeuwenoord, N. J., Bader, J. E., Everts, B., den Dulk, H., Overkleeft, H. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.102 · Cited by 142 · see citing works
PDK1 inhibition is a novel therapeutic target in multiple myeloma
Fujiwara, S., Kawano, Y., Yuki, H., Okuno, Y., Nosaka, K., Mitsuya, H., & Hata, H. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.527 · Cited by 141 · see citing works
Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
Rückrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., Overkleeft, H. S., Kalbacher, H., & Driessen, C. (2009) · Leukemia · doi:10.1038/leu.2009.8 · Cited by 139 · see citing works
ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer
Park, S. H., Chang, C., Safi, R., Liu, X., Baldi, R. M., Jasper, J. S., Anderson, G. R., Liu, T., Rathmell, J. C., Dewhirst, M. W., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.026 · Cited by 139 · see citing works
Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma
Ren, F., Wu, H., Lei, Y., Zhang, H., Liu, R., Zhao, Y., Chen, X., Zeng, D., Tong, A., Chen, L., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-81 · Cited by 136 · see citing works
Targeting metabolic reprogramming in KRAS-driven cancers
Kawada, K., Toda, K., & Sakai, Y. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1156-4 · Cited by 136 · see citing works
Early Detection of Tumor Response to Chemotherapy by 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography: The Effect of Cisplatin on a Fibrosarcoma Tumor Model In vivo
Leyton, J., Latigo, J. R., Perumal, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4008 · Cited by 132 · see citing works
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
Ling, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043331 · Cited by 130 · see citing works
Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner, K., & Melton, D. W. (2010) · PubMed · Cited by 130 · see citing works
The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
Anderson, K. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8919 · Cited by 129 · see citing works
Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death
Catanzaro, D., Gaude, E., Orso, G., Giordano, C., Guzzo, G., Rasola, A., Ragazzi, E., Caparrotta, L., Frezza, C., & Montopoli, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4945 · Cited by 126 · see citing works
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
Thompson, R. M., Dytfeld, D., Reyes, L., Robinson, R. M., Smith, B. M., Manevich, Y., Jakubowiak, A. J., Komarnicki, M. A., Przybyłowicz-Chalecka, A., Szczepaniak, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16262 · Cited by 126 · see citing works
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Wu, C., Wangpaichitr, M., Feun, L. G., Kuo, M. T., Robles, C., Lampidis, T. J., & Savaraj, N. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-25 · Cited by 125 · see citing works
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
Deblois, G., Smith, H. W., Tam, I. S., Gravel, S., Caron, M., Savage, P., Labbé, D. P., Bégin, L. R., Tremblay, M. L., Park, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12156 · Cited by 120 · see citing works
The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
Papaevangelou, E., de Almeida, G. S., Box, C., deSouza, N. M., & Chung, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31392 · Cited by 119 · see citing works
The glucose‐deprivation network counteracts lapatinib‐induced toxicity in resistant ErbB2‐positive breast cancer cells
Komurov, K., Tseng, J., Muller, M., Seviour, E. G., Moss, T. J., Yang, L., Nagrath, D., & Ram, P. T. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.25 · Cited by 117 · see citing works
Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis
Ruprecht, B., Zaal, E. A., Zecha, J., Wu, W., Berkers, C. R., Küster, B., & Lemeer, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2976 · Cited by 117 · see citing works
Self-citation
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells
Du, Z., Zhang, H.-Y., Meng, X., Guan, Y., & Wang, H.-Q. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-56 · Cited by 111 · see citing works
Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers.
Yang, Y., Liu, H., Li, Z., Zhao, Z., Yip-Schneider, M., Fan, Q., Schmidt, C. M., Chiorean, E. G., Xie, J., Liang Cheng, C., et al. (2011) · PubMed Central · Cited by 109 · see citing works
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
Cesi, G., Walbrecq, G., Zimmer, A. D., Kreis, S., & Haan, C. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0667-y · Cited by 103 · see citing works
Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer
Wangpaichitr, M., Wu, C., Li, Y. Y., Nguyen, D. J. M., Kandemir, H., Shah, S. S., Chen, S., Feun, L. G., Prince, J. S., Kuo, M. T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17568 · Cited by 101 · see citing works
Energy Metabolism in a Matched Model of Radiation Resistance for Head and Neck Squamous Cell Cancer
Mims, J., Bansal, N., Bharadwaj, M. S., Chen, X., Molina, A. J. A., Tsang, A. W., & Furdui, C. M. (2015) · Radiation Research · doi:10.1667/rr13828.1 · Cited by 100 · see citing works
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction
Jin, X., Pan, Y., Wang, L., Ma, T., Zhang, L., Tang, A., Billadeau, D. D., Wu, H., & Huang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3143 · Cited by 98 · see citing works
Oxidative stress and proteasome inhibitors in multiple myeloma
Lipchick, B. C., Fink, E. E., & Nikiforov, M. A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.029 · Cited by 95 · see citing works
The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells
Wangpaichitr, M., Sullivan, E. J., Theodoropoulos, G., Wu, C., You, M., Feun, L. G., Lampidis, T. J., Kuo, M. T., & Savaraj, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0599 · Cited by 94 · see citing works
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
Chen, R., Lai, L. A., Sullivan, Y., Wong, M., Wang, L., Riddell, J., Jung, L., Pillarisetty, V. G., Brentnall, T. A., & Pan, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-08436-6 · Cited by 92 · see citing works
Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotypePreprint
Ohanna, M., Cerezo, M., Nottet, N., Bille, K., Didier, R., Béranger, G. E., Mograbi, B., Rocchi, S., Yvan‐Charvet, L., Ballotti, R., et al. (2018) · Genes & Development · doi:10.1101/gad.305854.117 · Cited by 91 · see citing works
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
Balsas, P., Galán‐Malo, P., Marzo, I., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.09.011 · Cited by 87 · see citing works
Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism
Rashmi, R., Huang, X., Floberg, J. M., Elhammali, A. E., McCormick, M. L., Patti, G. J., Spitz, D. R., & Schwarz, J. K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2367 · Cited by 87 · see citing works
Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome
Benito, A., Polat, I. H., Noé, V., Ciudad, C. J., Marín, S., & Cascante, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21601 · Cited by 83 · see citing works
Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells
Song, I. S., Kim, H. K., Lee, S. R., Jeong, S. H., Kim, N., Ko, K. S., Rhee, B. D., & Han, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28149 · Cited by 82 · see citing works
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer
de Wilt, L. H. A. M., Jansen, G., Assaraf, Y. G., et al. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.009 · Cited by 80 · see citing works
PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC
Kim, M. J., Choi, Y., Park, S. Y., Jang, S. Y., Lee, J. Y., Ham, H. J., Kim, B., Jeon, H., Kim, J. H., Kim, J., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0061 · Cited by 80 · see citing works
Rewired Metabolism in Drug-resistant Leukemia Cells
Stäubert, C., Bhuiyan, H., Lindahl, A., Broom, O. J., Zhu, Y., Islam, S., Linnarsson, S., Lehtiö, J., & Nordström, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618769 · Cited by 79 · see citing works
Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
Fiorillo, M., Sotgia, F., Sisci, D., Cappello, A. R., & Lisanti, M. P. (2017) · Oncotarget · doi:10.18632/oncotarget.15852 · Cited by 77 · see citing works
Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel
Sun, H., Zhu, A.-Y., Zhou, X., & Wang, F. (2017) · Oncotarget · doi:10.18632/oncotarget.16991 · Cited by 77 · see citing works
N′1,N′3-Dimethyl-N′1,N′3-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)
Wangpaichitr, M., Wu, C., You, M., Maher, J. C., Dinh, V., Feun, L. G., & Savaraj, N. (2009) · Cancers · doi:10.3390/cancers1010023 · Cited by 73 · see citing works
Plasticity of melanoma and EMT-TF reprogramming
Tulchinsky, E. M., Pringle, J. H., Caramel, J., & Ansieau, S. (2013) · Oncotarget · doi:10.18632/oncotarget.1662 · Cited by 67 · see citing works
Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy
Masamha, C. P., & LaFontaine, P. R. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26814 · Cited by 66 · see citing works
Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer
Beatty, A., Fink, L. S., Singh, T., Strigun, A., Peter, E., Ferrer, C. M., Nicolas, É., Cai, K. Q., Moran, T. P., Reginato, M. J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0407 · Cited by 65 · see citing works
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen, C., Kraus, M., Joerger, M., Rosing, H., Bader, J. E., Hitz, F., Berset, C., Xyrafas, A., Hawle, H., Berthod, G., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.135780 · Cited by 61 · see citing works
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis
Lee, J. Y., Lee, I., Chang, W. J., Ahn, S. M., Kim, H. S., Kim, H. S., Yoo, K. H., Jung, K. S., Song, H., Cho, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9523 · Cited by 61 · see citing works
ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells
Aird, K. M., Allensworth, J. L., Batinic̈‐Haberle, I., Lyerly, H. K., Dewhirst, M. W., & Devi, G. R. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1568-1 · Cited by 60 · see citing works
Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism
Liu, Y., Chun-xi, H., & Huang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.20663 · Cited by 53 · see citing works
Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines
Shinohara, Y., Yamamoto, K., Kogure, K., et al. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90142-2 · Cited by 52 · see citing works
Targeting cisplatin-resistant human tumor cells with metabolic inhibitors
Sullivan, E. J., Kurtoğlu, M., Brenneman, R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2366-8 · Cited by 49 · see citing works
The Role of Pyruvate Kinase M2 in Cancer Metabolism
Liu, V. M., & Heiden, M. G. V. (2015) · Brain Pathology · doi:10.1111/bpa.12311 · Cited by 49 · see citing works
Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway
Fukuda, S., Miyata, H., Miyazaki, Y., Makino, T., Takahashi, T., Kurokawa, Y., Yamasaki, M., Nakajima, K., Takiguchi, S., Mori, M., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4522-3 · Cited by 45 · see citing works
Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells
Ambrosio, M. R., D’Esposito, V., Costa, V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22552 · Cited by 45 · see citing works
Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells
Catanzaro, D., Nicolosi, S., Cocetta, V., Salvalaio, M., Pagetta, A., Ragazzi, E., Montopoli, M., & Pasut, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24708 · Cited by 45 · see citing works
First-line treatment of acute lymphoblastic leukemia with pegasparaginase
Pession, A. (2009) · Biologics · doi:10.2147/btt.s3295 · Cited by 37 · see citing works
Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming
Ma, L., & Cheng, Q. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.079 · Cited by 35 · see citing works
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway
Fuchs, D., Berges, C., Opelz, G., Daniel, V., & Naujokat, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.012 · Cited by 34 · see citing works
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
Shi, H., Zhang, W., Zhi, Q., & Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5467-2 · Cited by 33 · see citing works
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor
Zhu, Y., Lu, L., Qiao, C., Shan, Y., Li, H., Qian, S., Hong, M., Zhao, H., Li, J., Yang, Z., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0157-8 · Cited by 32 · see citing works
Metabolism – A cornerstone of cancer initiation, progression, immune evasion and treatment response
Lunt, S. Y., & Fendt, S. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.12.006 · Cited by 31 · see citing works
PGAMgnam Style: A Glycolytic Switch Controls Biosynthesis
Chaneton, B., & Gottlieb, E. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.014 · Cited by 30 · see citing works
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
Niewerth, D., Kaspers, G. J. L., Jansen, G., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0312-z · Cited by 26 · see citing works
Corrigendum to “Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model”
Songia, P., Porro, B., Chiesa, M., Myasoedova, V., Alamanni, F., Tremoli, E., & Poggio, P. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3575348 · Cited by 24 · see citing works
Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics
Jain, A. Y., Jahagirdar, D., Nilendu, P., & Sharma, N. K. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1356231 · Cited by 21 · see citing works
Metformin‐induced alterations in nucleotide metabolism cause 5‐fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma
Mynhardt, C., Damelin, L. H., Jivan, R., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26291 · Cited by 20 · see citing works
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
Song, I.-S., Jeong, Y. J., Jeong, S. H., Heo, H. J., Kim, H. K., Lee, S. R., Ko, T. H., Youm, J. B., Kim, N., Ko, K. S., et al. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.104 · Cited by 18 · see citing works
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
Franke, N. E., Kaspers, G. J. L., Assaraf, Y. G., van Meerloo, J., Niewerth, D., Kessler, F. L., Poddighe, P. J., Kole, J., Smeets, S. J., Ylstra, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11340 · Cited by 18 · see citing works
BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
Li, Y.-Y., Wu, C., Chen, S.-M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6882 · Cited by 16 · see citing works
Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines
Dettmer, S., Theile, D., Schäfer, J. C., Seckinger, A., Burhenne, J., & Weiß, J. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1276-9 · Cited by 5 · see citing works

Flagged first, then by citations

Sorted by citations

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works
The roles and regulation of TBX3 in development and disease
Khan, S. F., Damerell, V., Omar, R., Du Toit, M., Khan, M., Maranyane, H. M., Mlaza, M., Bleloch, J., Bellis, C., Sahm, B. D. B., et al. (2020) · Gene · doi:10.1016/j.gene.2019.144223 · Cited by 99 · see citing works
“These findings are interesting because the methylation of TBX3 in glioblastoma is associated with resistance to standard therapy and metabolic pathways have been implicated as important mediators of resistance to anti-cancer agents (Etcheverry et al., 2010; Zaal and Berkers, 2018).”
Background
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer
Cargill, K. R., Stewart, C. A., Park, E. M., Ramkumar, K., Gay, C. M., Cardnell, R. J., Wang, Q., Diao, L., Shen, L., Fan, Y.-H., et al. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00270-9 · Cited by 62 · see citing works
Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58 · see citing works
The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer
Kansara, S., Singh, A., Badal, A. K., Rani, R., Baligar, P., Garg, M., & Pandey, A. K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.06.007 · Cited by 32 · see citing works
A two-way street - cellular metabolism and myofibroblast contraction
Noom, A., Sawitzki, B., Knaus, P., & Duda, G. N. (2024) · npj Regenerative Medicine · doi:10.1038/s41536-024-00359-x · Cited by 31 · see citing works
Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
Mendes, C., & Serpa, J. (2019) · Antioxidants · doi:10.3390/antiox8120603 · Cited by 21 · see citing works

Authors: Zaal, E. A., & Berkers, C. R.
Affiliations: Utrecht University (NL)
Corresponding author: Berkers, Celia R.
ORCID: Zaal, Esther A.
Berkers, Celia R.
Venue: Frontiers in Oncology
Publisher: Frontiers Media SA
Published: 2018-11-02
Volume: 8
Pages: 500-500
ISSN: 2234-943X (ISSN-L)
DOI: 10.3389/fonc.2018.00500
PMC: PMC6230982
OpenAlex: W2899130161
Cited by: 272
References: 186
Citations by year: 2026: 14 · 2025: 28 · 2024: 37 · 2023: 45 · 2022: 45 · 2021: 45 · 2020: 48 · 2019: 10
FWCI: 2.68
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Frontiers in Oncology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders: Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: cancer metabolism, drug resistance, chemoresistance, anticancer agents, metabolic pathways, overcoming drug resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Influence of Metabolism on Drug Response in Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks